 BALA CYNWYD, Pa., Sept. 16, 2021 GLOBE NEWSWIRE -- Larimar Therapeutics, Inc. Larimar Nasdaq: LRMR, a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1x1 investor meetings at the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases Genetic Medicines 1x1 Event. The event is taking place virtually September 22-23, 2021. 